Greenovation Biotech GmbH announces completion of its Phase I safety study for moss-aGal targeting Fabry disease.
FREIBURG, Germany, October 17, 2017 — Greenovation Biotech GmbH, a clinical-stage biopharmaceutical company developing therapies to treat orphan diseases today announces completion of its Phase I moss-aGal study in Fabry disease (FD).Greenovation expects to report data from the study later this year.
The Phase I study was designed as a single dose administered in six patients suffering from FD. Primary endpoints were safety and pharmacokinetics. The patients were monitored over 28 days. The single dose of moss-aGal was well tolerated by patients.
Moss-aGal is the first clinical product produced in Greenovation`s moss-based technology and therefore the first ever moss-made drug candidate tested in humans.
"We would particularly like to thank the patient volunteers who participated in this clinical study. The results may help to develop a drug that will hopefully improve the treatment of Fabry disease in future. In preclinical studies moss-aGal demonstrated pharmacodynamic differences as compared to approved drugs. These will hopefully translate to improvements in patients’ quality of life. The expected positive Phase I results will pave the way for quick initiation of Phase II/III studies.” says Dr. Thomas Frischmuth, CEO of Greenovation.
Contact and further information:
Greenovation Biotech GmbH
Manon Kirstein,
Tel: +49 761 470 99 0
Email: mkirstein@greenovation.com
